301239 Chengdu Bright Eye Hospital Group
- 51.83
- -3.41-6.17%
Chengdu Bright Eye Hospital Group News
Puri Ophthalmology (301239): Expect profitability to return to an upward range after consumption warms up
Puri Ophthalmology (301239): Mergers and acquisitions accelerate profit side under short-term pressure
Puri Ophthalmology (301239) 2024 Interim Report Review: The Interim Report is in line with expectations, and the long-term expansion layout is in line with expectations
Puri Ophthalmology (301239): The new hospital's centralized opening performance is under pressure in the short term
Puri Ophthalmology (301239) 2023 Report and 2024 Quarterly Report Review: The revenue side is in line with expectations, cataract revenue growth is impressive
Puri Ophthalmology (301239): Under pressure from 23 years of high performance growth base, 24Q1 performance is under pressure
Dongwu Securities released a research report on April 25 stating that it gave Puri Ophthalmology (301239.SZ) a purchase rating. The main reasons for the rating include: 1) Cataract achieved rapid growth in 2023, and gross margins of various businesses inc
Puri Ophthalmology (301239): A rising star in the ophthalmology industry continues to expand from the bottom up
Puri Ophthalmology (301239): Performance is in line with expectations and is steadily advancing the “national chain+city integration” layout strategy
Puri Ophthalmology (301239): Maintaining rapid growth in performance and continuing to build a highland of talents
Puri Ophthalmology (301239) 2023 Third Quarter Report Review: Maintaining High Growth in the Third Quarter, Repurchasing Shares Shows Confidence in Long-term Development
Puri Ophthalmology (301239) Company Review: Profitability Is Gradually Realized, Talent Escalation Is Steady Expansion
Puri Ophthalmology (301239): The first repurchase announcement shows confidence in long-term development, and the company's value is yet to be realized
Puri Ophthalmology (301239): Accelerating share repurchases during the expansion period and cohesion
Puri Ophthalmology (301239): Cataract business has doubled and profitability has increased dramatically
Puri Ophthalmology (301239): Performance Exceeded Expectations, Increased Profitability
Puri Ophthalmology (301239): Resuming rapid growth and improving profitability
Puri Ophthalmology (301239): Various businesses have accelerated their recovery and profitability has greatly improved
Puri Ophthalmology (301239): Strong hospitals combined quickly contributed to continuous improvement in profit indicators
Puri Ophthalmology (301239) Review: Performance Flexibility Releases Outstanding Performance in Underlying Eye Diseases
Analysis
Price Target
No Data
No Data